Pharma Focus Europe

MiNA Therapeutics and Nippon Shinyaku Team Up to Develop RNAa Therapeutics for Rare Neurodegenerative Diseases

Friday, April 05, 2024

MiNA Therapeutics, a leader in small activating RNA (RNAa) therapeutics, has announced a collaborative research and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), a Japanese pharmaceutical company dedicated to addressing high unmet medical needs. This collaboration aims to discover and potentially develop RNAa therapeutic candidates for rare neurodegenerative diseases without current treatment options.

Under the agreement, MiNA Therapeutics will use its proprietary RNAa algorithm and technology platform to identify and characterize RNAa molecules targeting rare genetic diseases of the central nervous system (CNS). Nippon Shinyaku will have the option to acquire an exclusive license for further research, development, and commercialization based on initial preclinical results.

Robert Habib, MiNA's Chief Executive Officer, expressed excitement about the collaboration, highlighting Nippon Shinyaku's commitment to rare genetic diseases and strong R&D capabilities. He emphasized the unique clinical benefits demonstrated by MiNA's RNAa therapeutic platform in previous studies.

Financial terms of the agreement were not disclosed, but Nippon Shinyaku will provide upfront payments and development milestone payments to MiNA. Additional milestone payments and royalties will be tied to the progress and sales of any products developed under the agreement.

MiNA's RNAa platform has been clinically validated in over 120 patients. It offers the potential to address any gene by correcting the root cause of defective genes, allowing the body to self-correct. RNAa medicines work at the gene level, offering the potential to treat diseases currently considered "undruggable."

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva